Treatment of chronic hepatitis due to hepatitis B and hepatitis delta virus coinfection.
Entry inhibitor
HBsAg release blocker
Hepatitis delta virus
IFN-lambda
Peg-IFN
Prenylation inhibitor
Journal
International journal of antimicrobial agents
ISSN: 1872-7913
Titre abrégé: Int J Antimicrob Agents
Pays: Netherlands
ID NLM: 9111860
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
05
03
2019
revised:
07
09
2019
accepted:
15
09
2019
pubmed:
22
9
2019
medline:
17
4
2020
entrez:
22
9
2019
Statut:
ppublish
Résumé
An estimated 20-40 million individuals worldwide are infected with hepatitis delta virus (HDV), mostly with rapidly evolving liver disease. Therapy of chronic HDV infection remains an unmet need. To date, only interferon (IFN)-based therapy is recommended for HDV infection and response rates are unsatisfactory; in addition, many patients are intolerant to or ineligible for IFN treatment. In recent years, innovative approaches have been in development, including the following: targeting virus entry into hepatocytes; inhibition of the host enzyme farnesyltransferase by prenylation inhibitors, leading to inhibition of complete virion formation and release; blockade of hepatitis B surface antigen (HBsAg) secretion, inhibiting virus release; and IFN-lambda, which causes fewer adverse effects than IFN-alfa. Clinical trials are ongoing with encouraging preliminary results.
Identifiants
pubmed: 31541699
pii: S0924-8579(19)30255-9
doi: 10.1016/j.ijantimicag.2019.09.012
pii:
doi:
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
697-701Informations de copyright
Copyright © 2019 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.